Comparative Pharmacology
Head-to-head clinical analysis: NIASPAN versus NICOLAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NIASPAN versus NICOLAR.
NIASPAN vs NICOLAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Niacin (nicotinic acid) reduces hepatic production of VLDL and LDL, and increases HDL by inhibiting diacylglycerol acyltransferase-2 (DGAT2) and reducing hepatic triglyceride synthesis. It also decreases the catabolism of HDL apolipoproteins A-I and A-II.
Niacin (nicotinic acid) reduces hepatic production of VLDL and LDL by inhibiting diacylglycerol acyltransferase-2 (DGAT2) and decreasing free fatty acid mobilization from adipose tissue via activation of GPR109A (HM74A) receptor, leading to reduced triglyceride and LDL cholesterol synthesis. It also raises HDL cholesterol by decreasing hepatic clearance of apo A-I.
Starting dose: 500 mg orally once daily at bedtime; after 4 weeks, increase to 1000 mg once daily; then titrate to maintenance dose of 1500-2000 mg once daily; maximum dose: 2000 mg/day.
NICOLAR (niacin extended-release) is typically initiated at 500 mg orally once daily at bedtime, after a low-fat snack. The dose is increased by 500 mg every 4 weeks as tolerated, up to a maximum of 2000 mg once daily.
None Documented
None Documented
Terminal half-life is 20-45 minutes (immediate-release) but due to prolonged release formulation of Niaspan, the half-life is extended to 2-4 hours for total nicotinic acid and 12 hours for nicotinuric acid, allowing once-daily dosing.
Terminal elimination half-life is 14-24 hours in adults with normal renal function; clinically, this supports twice-daily dosing. In moderate renal impairment (CrCl 30-59 mL/min), half-life extends to 24-36 hours, requiring dose adjustment.
Primarily renal (60-76% as unchanged drug and metabolites). Hepatic metabolism is extensive; less than 2% excreted in feces.
Primarily renal (60-70% as unchanged drug and metabolites), with 10-20% biliary/fecal. Hepatic metabolism to inactive metabolites accounts for ~30% of elimination.
Category C
Category C
Antilipemic agent
Antilipemic agent